• Profile

Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: A double-dummy, randomized, controlled trial

Addiction Feb 11, 2022

Researchers conducted a randomized, controlled, double-dummy, blinded, non-inferiority trial, with the aim of measuring and evaluating clinical response to nasal naloxone in opioid overdoses in the prehospital environment.

  • Men and women aged above 18 years with miosis, rate of respiration ≤ 8/min, and Glasgow Coma Score < 12/15 were randomized to a commercially available 1.4 mg/0.1 mL intranasal naloxone or 0.8 mg/2 mL naloxone administered intramuscularly.

  • In the per-protocol population, analysis of 201 participants was done.

  • In 196 cases, heroin was suspected.

  • Relative to 0.8 mg intramuscular naloxone, intranasal naloxone (1.4 mg/0.1 mL) was identified as less efficient for return to spontaneous breathing within 10 minutes in overdose patients in the prehospital environment when compared head-to-head.

  • Eighty percent of the participants had restored breathing after receiving one dose of intranasal naloxone at 1.4 mg/0.1 mL with few mild adverse reactions.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen